Home > News > Detailed Positive ABRAXANE Phase III Data Released
December 8th, 2003
Detailed Positive ABRAXANE Phase III Data Released
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.
Happily ever after: Scientists arrange protein-nanoparticle marriage: New biotech method could lead to development of HIV vaccine, targeted cancer treatment April 20th, 2015
Optical resonance-based biosensors designed for medical applications April 18th, 2015
Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015
Novel nanoparticles could save soldiers' lives after explosions April 15th, 2015